Form 4: Schrodinger Inc. Chief Medical Officer Margaret Dugan Acquires 60,000 Stock Options

Margaret Dugan, Chief Medical Officer of Schrodinger, Inc., was granted 60,000 stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• Margaret Dugan, the Chief Medical Officer of Schrodinger, Inc., filed a Form 4 with the SEC.
• The filing reports that she was granted 60,000 stock options on March 4, 2024, with an exercise price of $25.24.
• The options vest over a four-year period, starting with 25% on March 4, 2025, and the remainder in equal monthly installments through March 4, 2028.
• Following the transaction, Ms. Dugan directly owns 60,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a routine event, but it indicates confidence in the company's future performance and aligns executive interests with shareholders.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Moderna, BioNTech, and Vertex Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedule of these options is fairly standard, with a typical four-year vesting period.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to drive long-term value.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates